NCT03277131View on ClinicalTrials.gov

DURAFIBER Ag Post-Market Clinical Follow-Up

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

June 19, 2019

Study Completion Date

June 19, 2019

Conditions
Wounds and InjuriesVenous Leg UlcerInfection
Interventions
DEVICE

DURAFIBER Ag

DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing

Trial Locations (7)

HU3 2JZ

Hull & East Riding Hospitals NHS Trust, Hull

PR2 8DW

Lancashire Care NHS Foundation Trust, Preston

S75 2EP

Barnsley Hospital NHS Foundation Trust, Barnsley

CF14 4XW

Cardiff & Vale University Healthcare Board, Cardiff

NE63 0HP

Northumbria Healthcare NHS Foundation Trust, Ashington

BD9 6RJ

Bradford Teaching Hospitals NHS Foundation Trust, Bradford

NE3 3HD

Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle

All Listed Sponsors
lead

Smith & Nephew, Inc.

INDUSTRY

NCT03277131 - DURAFIBER Ag Post-Market Clinical Follow-Up | Biotech Hunter | Biotech Hunter